Media Summary: Markham C. Luke from CDER's Office of Generic Drugs discusses Myong-Jin Kim from CDER's Office of Generic Drugs discusses non- The purpose of this webinar was to provide current and prospective generic drug applicants insight on how PSGs are developed, ...

Product Specific Guidances For Complex - Detailed Analysis & Overview

Markham C. Luke from CDER's Office of Generic Drugs discusses Myong-Jin Kim from CDER's Office of Generic Drugs discusses non- The purpose of this webinar was to provide current and prospective generic drug applicants insight on how PSGs are developed, ... Mitchell Frost from CDER's Office of Generic Drugs discusses study population and terminology, bioequivalence studies with ... Dave Coppersmith and Myong-Jin Kim from CDER's Office of Generic Drugs provide information on Rob Lionberger, Lei Zhang, CDR Christine Le, Myong-Jin Kim, Markham Luke, Mitchell Frost, Paramjeet Kaur, David Coppersmith ...

Lei Zhang, Deputy Director of the Office of Research and Standards in FDA's Office of Generic Drugs, explains A presentation and panel discuss potential gaps in Presenters and presentations include: Advances in Iron Colloid Products: Denise Conti, CDER Office of Generic Drugs, provides an overview on orally inhaled and nasal drug

Photo Gallery

Product-Specific Guidances for Complex Generic Drugs
Non-Complex Drug Products and Product-Specific Guidances
AGDD 2025 | D1S01 - Product-Specific Guidance for Complex Products: From Research to Standards
Facilitating Generic Drug Product Development through Product-Specific Guidances
Product-Specific Guidance Fundamentals from a Clinical Perspective
Complex Generics: Topical Products, Part 1
Product Specific Guidances (PSGs) (3of16) Generic Drugs Forum 2020
Panel Discussion on Product-Specific Guidances
Product Specific Guidances Webinar – Opening Remarks
Complex Product Characterization/Analysis - Session 2A
Complex Generics: Complex Injectables, Ophthalmic, and Otic Products, Part 1
Complex Generics: Complex Injectables, Ophthalmic, and Otic Products, Part 2
View Detailed Profile
Product-Specific Guidances for Complex Generic Drugs

Product-Specific Guidances for Complex Generic Drugs

Markham C. Luke from CDER's Office of Generic Drugs discusses

Non-Complex Drug Products and Product-Specific Guidances

Non-Complex Drug Products and Product-Specific Guidances

Myong-Jin Kim from CDER's Office of Generic Drugs discusses non-

AGDD 2025 | D1S01 - Product-Specific Guidance for Complex Products: From Research to Standards

AGDD 2025 | D1S01 - Product-Specific Guidance for Complex Products: From Research to Standards

This session provided insights into the

Facilitating Generic Drug Product Development through Product-Specific Guidances

Facilitating Generic Drug Product Development through Product-Specific Guidances

The purpose of this webinar was to provide current and prospective generic drug applicants insight on how PSGs are developed, ...

Product-Specific Guidance Fundamentals from a Clinical Perspective

Product-Specific Guidance Fundamentals from a Clinical Perspective

Mitchell Frost from CDER's Office of Generic Drugs discusses study population and terminology, bioequivalence studies with ...

Complex Generics: Topical Products, Part 1

Complex Generics: Topical Products, Part 1

FDA discusses topics in

Product Specific Guidances (PSGs) (3of16) Generic Drugs Forum 2020

Product Specific Guidances (PSGs) (3of16) Generic Drugs Forum 2020

Dave Coppersmith and Myong-Jin Kim from CDER's Office of Generic Drugs provide information on

Panel Discussion on Product-Specific Guidances

Panel Discussion on Product-Specific Guidances

Rob Lionberger, Lei Zhang, CDR Christine Le, Myong-Jin Kim, Markham Luke, Mitchell Frost, Paramjeet Kaur, David Coppersmith ...

Product Specific Guidances Webinar – Opening Remarks

Product Specific Guidances Webinar – Opening Remarks

Lei Zhang, Deputy Director of the Office of Research and Standards in FDA's Office of Generic Drugs, explains

Complex Product Characterization/Analysis - Session 2A

Complex Product Characterization/Analysis - Session 2A

A presentation and panel discuss potential gaps in

Complex Generics: Complex Injectables, Ophthalmic, and Otic Products, Part 1

Complex Generics: Complex Injectables, Ophthalmic, and Otic Products, Part 1

Presenters and presentations include: Advances in Iron Colloid Products:

Complex Generics: Complex Injectables, Ophthalmic, and Otic Products, Part 2

Complex Generics: Complex Injectables, Ophthalmic, and Otic Products, Part 2

FDA discusses additional topics in

Guidances and FAQ for Orally Inhaled and Nasal Drug Products (32of39) Complex Generics 2018

Guidances and FAQ for Orally Inhaled and Nasal Drug Products (32of39) Complex Generics 2018

Denise Conti, CDER Office of Generic Drugs, provides an overview on orally inhaled and nasal drug